ABSTRACT
Introduction
Bradykinin is regarded as a substrate of the CD26/DPP-4 enzyme 1 . Research has revealed that bradykinin B2 receptor (B2R)
antagonists play a protective role against ischemia/reperfusion (I/R) injury, particularly in transplantation [2] [3] [4] [5] , but the significance of bradykinin in IR and the relationship between bradykinin and CD26/DPP-4 are not completely understood. It is accepted that the kallikrein-kinin system expresses potent biological activities through its final product, bradykinin 6 , and that bradykinin acts via two receptor subtypes. The bradykinin B1 receptor (B1R)
is up-regulated under inflammatory conditions, whereas B2R is constitutively expressed 7 . Some studies have shown that B1R
modulates the late phase of lung inflammation 8, 9 , while B2R is involved in full-stage airway responses, and mediates NF-kB activation in airway epithelial cells 10 . Identifying the bradykinin receptor subtypes involved at different stages during inflammation of the lung is crucial to improve our understanding of complex pulmonary conditions, including treatment (Tx)-induced lung I/R injury.
Primary graft dysfunction (PGD) following lung transplantation (LTx) has been described as an acute lung injury syndrome within 72 hr of transplantation that is triggered by marked I/R injury, and is associated with pulmonary edema, severe hypoxemia, bilateral pulmonary infiltrates, and other conditions. Importantly, all symptoms have been shown to occur no later than 72 hr after LTx 11, 12 . The treatment for PGD remains unacceptable: patients undergoing LTx with PGD have a mortality rate up to 60% 13 . It has been demonstrated 14 that perfusion with a specific inhibitor of DPP-4 significantly decreases the incidence and severity of pulmonary PGD and improves recovery after LTx.
In addition, the severity of PGD was shown to be related to the time of cold ischemia 14, 15 . Extended cold ischemia time better reflects the role of the target protein, further broadening the scope of CD26/DPP -4 inhibitors for potential therapeutic use.
As a proof of concept approach, and due to the timing of PGD, we chose to investigate the role of B2R in I/R after transplantation. Next, we established a rat LTx model to investigate the role of bradykinin in PGD and preliminarily discuss the relationship between bradykinin and CD26/DPP-4. Finally, we ascertained whether the severity of I/R injury correlates with augmentation of B2R.
Methods
The animal protocol was approved by the Animal Ethics 
Recipient procedure
Anesthesia, intubation, and ventilation were applied to the recipients as described above. All three structures (PV, PA , and main bronchus) were clamped and incised, and the cuffed respective donor structures inserted and fixed using a 6-0 nylon ligature. The transplanted lung was inflated, the thoracotomy closed, and the lung extubated. For the first two postoperative days, recipients received a standardized regimen of analgesic treatment.
Graft assessment
At the time of harvest, graft oxygenation was evaluated by sampling blood directly from the PV of the transplanted lung. The graft was harvested, divided into thirds, and stored at -80°C for further studies.
Wet/dry weight ratio
One part of each harvested lung was weighed and placed in an oven at 180°C for 48 hr. The portion was reweighed, and the ratio of the weight before and after drying was calculated. This assay reflects lung fluid content, indicating the extent of post reperfusion pulmonary edema.
MPO activity assay
Quantitative MPO activity was determined by measuring neutrophil migration into the graft. Lung tissue was homogenized with a tissue/buffer ratio of 50 mg/mL and absorbance was immediately measured at 450 nm. Enzyme activity was expressed as unit per gram of tissue protein (U/g).
Estimation of lipid peroxidation
This assay is based on the formation of a complex between malondialdehyde (MDA) and two molecules of thiobarbituric acid in an acid medium. MDA concentration is determined by measuring the absorbance at 532 nm and is expressed in µM.
Immunohistochemical staining for B2R
The tissue sections were incubated with rabbit polyclonal antibody to B2R according to manufacturer's instructions. Primary and biotinylated secondary antibody (horseradish peroxidase, HRP) binding were visualized by 3,30-diaminobenzidine. All cells were examined and classified as positive (brown-stained) or negative (not stained) for B2R.
Western blotting
Western blotting analysis was performed as routinely described. In brief, the protein was homogenized and separated by electrophoresis. The membrane was blocked and incubated with a rabbit polyclonal antibody to B2R, and subsequently incubated with a HRP secondary antibody (Abcam, Cambridge, UK). β-actin (Epitomics, Burlingame, A) was chosen as the loading control. The relative density of proteins to β-actin was analyzed with Odyssey (LI-COR, Lincoln, NE).
Reagents and drugs
The following drugs/kits were used: AB192 (bis(4- 
Statistical analysis
Statistical analysis was performed using GraphPad Prism (Version 6.01 for Windows) statistical software. Results are expressed as mean±SD. Student t tests were used to compare the significant differences between groups. Statistical significance was set at p<0.05.
Results

Oxygenation
At 48 hr post-treatment, oxygenation capacity was significantly higher in the AB192 group versus the LPD group 
Wet/dry weight ratio
Tissue edema was significantly less in the AB192 group versus the LPD group (6.46±0.26 vs. 8.55±0.28, p<0.05). There was no difference between the CON and Sham groups (5.17±0.14 vs. 5.40±0.14, p> 0.05). Tissue edema was significantly less in the CON and Sham groups compared to the AB192 group (p<0.05; Figure 1 ). 
MPO activity
At harvest, MPO was significantly lower in LPD group compared to the AB192 group (1.91±0.12 U/g vs. 3.38±0.12 U/g, 
Estimation of lipid peroxidation
Forty-eight hours after graft reperfusion, significantly lower MDA was observed in the LPD group compared to the AB192 group (1.97±0.14 µM vs. 3.04±0.14 µM, p<0.05). There 
Immunohistochemistry evaluation
Comparing histologic sections at 48 hr after reperfusion, grafts from the LPD group showed stronger positive staining in the lungs, inflammatory cells, alveolar macrophages (AM), and respiratory epithelial cells versus grafts from the AB192 group.
Conversely, grafts from the CON and Sham groups showed relatively negative staining. As shown in Figure 3 , there were more inflammatory cells in the Sham group compared to the CON group. Staining in the AM was only slightly visible. 
Western blotting
To verify the immunohistochemical results, we selected to investigate B2R for further analysis. The expression of B2R in the LPD and AB192 groups were significantly higher compared to the CON and Sham groups (p<0.05), while the expression of B2R was significantly higher in the LPD group versus the AB192 group (p<0.05). However, there was no difference in B2R expression between the CON and Sham groups (p>0.05) (Figure 4 ). . In contrast, DPP-4 is expressed on various epithelial, endothelial and lymphatic cellular surfaces 19 ,and cleaves many potent biological proteins. Thus the argument that bradykinin is a substrate of DPP-4 is not entirely confirmed. In our study, we found that bradykinin was down-regulated with DPP-4 inhibitor treatment, and therefore speculate that bradykinin is a competitive substrate of the DPP-4 enzyme. Finally, DPP-4 inhibition increased local pulmonary bradykinin levels. This effect correlated with ventilatory function and pulmonary structural integrity, as well as PGD after LTx. In addition, injection of a B2R antagonist combined with a specific DPP-4 inhibitor, attenuated IRI in lung grafts and enabled lung recovery.
There are several limitations to this study. First, our findings were based on a single time point, which did not allow for dynamic observations. Second, Lewis rats may be better for our experimental animals than SD rats. Third, the rats which had graft failure were excluded. Fourth, this study was a preliminarily investigation and thus alternative mechanisms were not investigated.
Conclusions
Bradykinin may be a competitive substrate of DPP-4, and decreased bradykinin levels may provide protective effects against I/R injury during LTx. This study provides a preliminary examination and discussion on the role of bradykinin in PGD and the relationship between bradykinin and CD26/DPP-4.
